The irreversible pan-HER (HER1, 2 and 4) inhibitor afatinib induced a sustained inhibition of EGFR and HER3 as sufficiently as the dual blockade of lapatinib and trastuzumab and provided a durable tumor regression in vitro [77,103,104]. The gene discussed is ERBB3; the disease is neoplasm.